Assembly Biosciences (NASDAQ:ASMB) Now Covered by HC Wainwright

HC Wainwright initiated coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a report published on Monday morning, Marketbeat reports. The firm issued a buy rating and a $50.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Assembly Biosciences’ Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at $0.87 EPS, Q4 2026 earnings at $0.86 EPS, FY2026 earnings at ($2.75) EPS, FY2027 earnings at $1.67 EPS, FY2028 earnings at ($1.34) EPS and FY2029 earnings at $3.07 EPS.

Assembly Biosciences Stock Performance

NASDAQ:ASMB opened at $26.15 on Monday. Assembly Biosciences has a one year low of $7.75 and a one year high of $26.25. The firm has a market cap of $200.57 million, a P/E ratio of -4.69 and a beta of 0.64. The firm has a 50-day simple moving average of $19.40 and a 200-day simple moving average of $14.58.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.73) by $0.40. The firm had revenue of $9.63 million during the quarter, compared to analyst estimates of $5.30 million. Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. On average, research analysts predict that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ASMB. B Group Inc. bought a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $799,000. Renaissance Technologies LLC raised its stake in shares of Assembly Biosciences by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock worth $1,495,000 after acquiring an additional 29,087 shares in the last quarter. Man Group plc purchased a new stake in Assembly Biosciences during the 4th quarter worth approximately $309,000. American Century Companies Inc. purchased a new stake in Assembly Biosciences during the 1st quarter worth approximately $113,000. Finally, JPMorgan Chase & Co. grew its position in Assembly Biosciences by 225.6% during the 4th quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 7,918 shares during the last quarter. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.